-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest data from Minet.
com shows that the sales of more than 500 varieties of chemical drug terminals in public hospitals in key provinces and cities will exceed 100 million yuan in 2021, and 92 of them will have a sales growth rate of more than 50%.
And new products are approved to drive market expansion
.
The total sales of 92 varieties exceeded 20 billion yuan, and the annual sales of 10 varieties exceeded 500 million yuan; the sales of 47 varieties doubled, and the sales of 2 exclusive varieties soared more than 400 times
.
In 2021, the chemical drug terminal sales of public hospitals in key provinces and cities will exceed 100 million yuan and the growth rate will exceed 50%.
Source: Minet.
com The competition pattern of public hospital terminals in key provinces and cities 92 varieties cover 13 treatment categories, focusing on anti-tumor and immune regulation Drugs (20 varieties), digestive system and metabolic drugs (17 varieties), cardiovascular and cerebrovascular drugs (11 varieties) and blood and hematopoietic system drugs (11 varieties)
.
Judging from the inclusion of medical insurance, 80 varieties belong to the 2021 version of the National Medical Insurance Catalogue (68 are Category B), accounting for about 87%
.
More than 40 varieties are exclusive varieties (calculated by drug name, including exclusive dosage forms), of which Novartis, Merck, BeiGene, Hengrui Medicine, Roche, Novo Nordisk and other companies have two or more varieties listed
.
The market exceeds 20 billion yuan, and the sales of 10 varieties exceed 500 million yuan.
In terms of sales, the total market size of 92 types of public hospital terminals in key provinces and cities will exceed 20 billion yuan in 2021, a year-on-year increase of 116.
8%
.
The sales of 10 varieties exceeded 500 million yuan, including Pertuzumab Injection (Roche), Ilaprazole Sodium for Injection (Livzon), Camrelizumab for Injection (Hengrui), Sacuba Trivalsartan Sodium Tablets (Novartis), Alectinib Hydrochloride Capsules (Roche), Sintilimab Injection (Cinda) and other exclusive varieties
.
In 2021, the terminal sales growth rate of public hospitals in key provinces and cities exceeds 500 million.
Source: Minet.
com, the terminal competition pattern of public hospitals in key provinces and cities Pertuzumab injection leads the sales of nearly 1 billion yuan, which is Roche A new type of anti-HER2 drug developed by the company, which produces anti-HER2 effects by inhibiting HER2 heterologous and homodimers, was approved for import in December 2018 for the adjuvant treatment of patients with HER2-positive early breast cancer
.
The product was included in the national medical insurance through negotiation in 2019, and began to rapidly increase in volume in 2020, with a sales growth rate of more than 2,000%, and a year-on-year increase of nearly 100% in 2021
.
Sales of terminal Pertuzumab injection in public hospitals in key provinces and cities (unit: RMB 10,000) Source: MINET.
com Competitive landscape of public hospitals in key provinces and cities K+-ATPase inhibits gastric acid secretion and is clinically used to treat duodenal ulcers
.
At present, the main dosage forms of ilaprazole that have been listed in China are enteric-coated tablets and injections, and there is only one manufacturer of Livzon
.
Ilaprazole sodium for injection was approved for marketing in January 2018, and was included in the national medical insurance through negotiation in 2019.
The sales growth rate in the past three years has reached triple digits
.
Sales of Ilaprazole Sodium for Injection in Terminals of Public Hospitals in Key Provinces and Cities (Unit: RMB 10,000) The compound preparation composed of enzyme inhibitor) and valsartan (angiotensin receptor antagonist) was approved for import as early as August 2017, and was included in the national medical insurance through negotiation in 2019.
The sales growth rate in the past three years has reached three number
.
At present, more than 10 generic drugs from Kelun, Nanjing Chia Tai Tianqing, Qilu, and Shiyao have submitted their listing applications.
In the future, as more and more generic drugs are approved, the market size of this variety is expected to expand further.
.
Sales of Sacubitril and Valsartan Sodium Tablets in Public Hospitals in Key Provinces and Cities In terms of growth rate, the sales growth rate of 47 varieties in 2021 will exceed 100%, of which 8 varieties will soar by more than 1000%, and edaravone dexcamphenol injection concentrated solution and dupilimumab injection will soar.
Over 400 times
.
In 2021, the terminal sales growth rate of public hospitals in key provinces and cities exceeds 1000%.
A class 1 new drug in the field of vascular disease.
It scientifically combines two active ingredients, edaravone and dexcamphenol, in a 4:1 ratio.
Significantly reduces cranial nerve damage caused by acute ischemic stroke
.
The product was approved for marketing in July 2020, and was included in the national medical insurance through negotiation in the same year, and sales in 2021 will soar nearly 600 times
.
Sales of edaravone dexbornol injection concentrated solution in public hospitals in key provinces and cities (unit: RMB 10,000) Source: Minet A fully human monoclonal antibody jointly developed with Regeneron, by blocking the downstream signal transduction of IL-4 and IL-13, relieves diseases mainly mediated by Th2 cells, including atopic dermatitis, asthma, allergic Rhinitis,
etc.
The product was included in the second batch of overseas new drugs urgently needed for clinical use, and was approved for import in June 2020
.
Sales of terminal dupulimumab injection in public hospitals in key provinces and cities (unit: 10,000 yuan) Source: Minet Generic drugs of companies such as Hansoh, Hansoh, and HEC were successively approved for production in 2019
.
This variety was included in the third batch of centralized procurement, and a number of "barefoot" enterprises were selected for centralized procurement and rapidly increased the volume, driving the sales of the entire variety to surge, with a year-on-year increase of more than 3,000% in 2021
.
Sales of Olanzapine Orally Disintegrating Tablets in Public Hospitals in Key Provinces and Cities (Unit: RMB 10,000) Source: Minet The two major policies of the terminal drug pattern force enterprises to transform into R&D innovation
.
Some of the 92 varieties of domestic class 1 new drugs are sourced: Minet.
com The competition pattern of public hospitals in key provinces and cities is driven by medical insurance, and many domestic innovative drugs have experienced rapid volume growth after they are launched, such as methanesulfonic acid, which was approved for marketing in 2020.
Ametinib Tablets (Haosen), Edaravone Dexbornol Injection Concentrated Solution (Xiansheng), Tislelizumab Injection (BeiGene), Zanubrutinib Capsules (BeiGene) In the same year, it was included in the national medical insurance through negotiation, and the sales growth rate in 2021 will reach 4 digits and above
.
Centralized procurement of 92 varieties (including those to be included) Source: MINET.
com Key Provinces and Cities Public Hospital Terminal Competition Landscape Centralized procurement mainly affects varieties in mature markets, and the market size of related varieties has declined due to substantial price reductions.
The five batches of oxaliplatin injections collected centrally are expected to see a sharp decline in the sales of oxaliplatin injections in public hospitals in 2022
.
For generic drugs that have been approved late and the market has not yet opened, "barefoot" companies can instead rely on centralized procurement to quickly increase the volume, driving the sales scale of the entire variety to increase, such as the third batch of olanzapine orally disintegrating tablets from centralized procurement
.
Source: Minet database Note: The database of chemical drug terminal competition in public hospitals in key provinces and cities of Minet is based on the chemical drug procurement data of nearly 700 public hospitals in sample provinces and cities in 20+ provinces and cities.
The monitored sample province and city sample hospital database
.
com shows that the sales of more than 500 varieties of chemical drug terminals in public hospitals in key provinces and cities will exceed 100 million yuan in 2021, and 92 of them will have a sales growth rate of more than 50%.
And new products are approved to drive market expansion
.
The total sales of 92 varieties exceeded 20 billion yuan, and the annual sales of 10 varieties exceeded 500 million yuan; the sales of 47 varieties doubled, and the sales of 2 exclusive varieties soared more than 400 times
.
In 2021, the chemical drug terminal sales of public hospitals in key provinces and cities will exceed 100 million yuan and the growth rate will exceed 50%.
Source: Minet.
com The competition pattern of public hospital terminals in key provinces and cities 92 varieties cover 13 treatment categories, focusing on anti-tumor and immune regulation Drugs (20 varieties), digestive system and metabolic drugs (17 varieties), cardiovascular and cerebrovascular drugs (11 varieties) and blood and hematopoietic system drugs (11 varieties)
.
Judging from the inclusion of medical insurance, 80 varieties belong to the 2021 version of the National Medical Insurance Catalogue (68 are Category B), accounting for about 87%
.
More than 40 varieties are exclusive varieties (calculated by drug name, including exclusive dosage forms), of which Novartis, Merck, BeiGene, Hengrui Medicine, Roche, Novo Nordisk and other companies have two or more varieties listed
.
The market exceeds 20 billion yuan, and the sales of 10 varieties exceed 500 million yuan.
In terms of sales, the total market size of 92 types of public hospital terminals in key provinces and cities will exceed 20 billion yuan in 2021, a year-on-year increase of 116.
8%
.
The sales of 10 varieties exceeded 500 million yuan, including Pertuzumab Injection (Roche), Ilaprazole Sodium for Injection (Livzon), Camrelizumab for Injection (Hengrui), Sacuba Trivalsartan Sodium Tablets (Novartis), Alectinib Hydrochloride Capsules (Roche), Sintilimab Injection (Cinda) and other exclusive varieties
.
In 2021, the terminal sales growth rate of public hospitals in key provinces and cities exceeds 500 million.
Source: Minet.
com, the terminal competition pattern of public hospitals in key provinces and cities Pertuzumab injection leads the sales of nearly 1 billion yuan, which is Roche A new type of anti-HER2 drug developed by the company, which produces anti-HER2 effects by inhibiting HER2 heterologous and homodimers, was approved for import in December 2018 for the adjuvant treatment of patients with HER2-positive early breast cancer
.
The product was included in the national medical insurance through negotiation in 2019, and began to rapidly increase in volume in 2020, with a sales growth rate of more than 2,000%, and a year-on-year increase of nearly 100% in 2021
.
Sales of terminal Pertuzumab injection in public hospitals in key provinces and cities (unit: RMB 10,000) Source: MINET.
com Competitive landscape of public hospitals in key provinces and cities K+-ATPase inhibits gastric acid secretion and is clinically used to treat duodenal ulcers
.
At present, the main dosage forms of ilaprazole that have been listed in China are enteric-coated tablets and injections, and there is only one manufacturer of Livzon
.
Ilaprazole sodium for injection was approved for marketing in January 2018, and was included in the national medical insurance through negotiation in 2019.
The sales growth rate in the past three years has reached triple digits
.
Sales of Ilaprazole Sodium for Injection in Terminals of Public Hospitals in Key Provinces and Cities (Unit: RMB 10,000) The compound preparation composed of enzyme inhibitor) and valsartan (angiotensin receptor antagonist) was approved for import as early as August 2017, and was included in the national medical insurance through negotiation in 2019.
The sales growth rate in the past three years has reached three number
.
At present, more than 10 generic drugs from Kelun, Nanjing Chia Tai Tianqing, Qilu, and Shiyao have submitted their listing applications.
In the future, as more and more generic drugs are approved, the market size of this variety is expected to expand further.
.
Sales of Sacubitril and Valsartan Sodium Tablets in Public Hospitals in Key Provinces and Cities In terms of growth rate, the sales growth rate of 47 varieties in 2021 will exceed 100%, of which 8 varieties will soar by more than 1000%, and edaravone dexcamphenol injection concentrated solution and dupilimumab injection will soar.
Over 400 times
.
In 2021, the terminal sales growth rate of public hospitals in key provinces and cities exceeds 1000%.
A class 1 new drug in the field of vascular disease.
It scientifically combines two active ingredients, edaravone and dexcamphenol, in a 4:1 ratio.
Significantly reduces cranial nerve damage caused by acute ischemic stroke
.
The product was approved for marketing in July 2020, and was included in the national medical insurance through negotiation in the same year, and sales in 2021 will soar nearly 600 times
.
Sales of edaravone dexbornol injection concentrated solution in public hospitals in key provinces and cities (unit: RMB 10,000) Source: Minet A fully human monoclonal antibody jointly developed with Regeneron, by blocking the downstream signal transduction of IL-4 and IL-13, relieves diseases mainly mediated by Th2 cells, including atopic dermatitis, asthma, allergic Rhinitis,
etc.
The product was included in the second batch of overseas new drugs urgently needed for clinical use, and was approved for import in June 2020
.
Sales of terminal dupulimumab injection in public hospitals in key provinces and cities (unit: 10,000 yuan) Source: Minet Generic drugs of companies such as Hansoh, Hansoh, and HEC were successively approved for production in 2019
.
This variety was included in the third batch of centralized procurement, and a number of "barefoot" enterprises were selected for centralized procurement and rapidly increased the volume, driving the sales of the entire variety to surge, with a year-on-year increase of more than 3,000% in 2021
.
Sales of Olanzapine Orally Disintegrating Tablets in Public Hospitals in Key Provinces and Cities (Unit: RMB 10,000) Source: Minet The two major policies of the terminal drug pattern force enterprises to transform into R&D innovation
.
Some of the 92 varieties of domestic class 1 new drugs are sourced: Minet.
com The competition pattern of public hospitals in key provinces and cities is driven by medical insurance, and many domestic innovative drugs have experienced rapid volume growth after they are launched, such as methanesulfonic acid, which was approved for marketing in 2020.
Ametinib Tablets (Haosen), Edaravone Dexbornol Injection Concentrated Solution (Xiansheng), Tislelizumab Injection (BeiGene), Zanubrutinib Capsules (BeiGene) In the same year, it was included in the national medical insurance through negotiation, and the sales growth rate in 2021 will reach 4 digits and above
.
Centralized procurement of 92 varieties (including those to be included) Source: MINET.
com Key Provinces and Cities Public Hospital Terminal Competition Landscape Centralized procurement mainly affects varieties in mature markets, and the market size of related varieties has declined due to substantial price reductions.
The five batches of oxaliplatin injections collected centrally are expected to see a sharp decline in the sales of oxaliplatin injections in public hospitals in 2022
.
For generic drugs that have been approved late and the market has not yet opened, "barefoot" companies can instead rely on centralized procurement to quickly increase the volume, driving the sales scale of the entire variety to increase, such as the third batch of olanzapine orally disintegrating tablets from centralized procurement
.
Source: Minet database Note: The database of chemical drug terminal competition in public hospitals in key provinces and cities of Minet is based on the chemical drug procurement data of nearly 700 public hospitals in sample provinces and cities in 20+ provinces and cities.
The monitored sample province and city sample hospital database
.
